
Anthropic has expanded its Claude Cowork tool to web and mobile platforms, allowing users to manage tasks across devices. Originally launched as a desktop app, Claude Cowork is designed to assist with general knowledge work, acting as an administrative coworker. The expansion aims to integrate AI into everyday business operations, similar to OpenAI's approach with Codex. This move allows users to perform tasks like report generation and content creation without relying solely on the desktop app, enhancing accessibility and functionality.
Read originalEarlier coverage that leads up to this article, and what followed. Lines connect each piece to the closest one after it, converging here.
© TechCrunch AIxAI's attempt to dismiss the NAACP's Clean Air Act lawsuit failed after a federal judge ruled that its gas turbines are not exempt mobile sources and that plaintiffs have standing. This legal setback confirms that AI infrastructure operators cannot bypass environmental permitting by classifying heavy industrial equipment as temporary or mobile. The ruling forces xAI to face scrutiny over air quality impacts at its Colossus data center, setting a precedent for how large-scale compute facilities are regulated under existing environmental laws.
© TechCrunch AIThe Rundown AI · April 20, 2026 · Related
Fireship · April 21, 2026 · Same story
Matt Wolfe · April 24, 2026 · Same story
Anthropic · April 28, 2026 · Same story
Anthropic · May 13, 2026 · Same story
TechCrunch AI · May 13, 2026 · Same story
MIT Technology Review AI · June 30, 2026 · Related
Lev Selector · July 3, 2026 · Related
Matt Wolfe · July 29, 2026 · Same story
TechCrunch AI · August 25, 2026 · Same story
The AI Daily Brief · October 11, 2026 · Same story
Skill Leap AI · October 20, 2026 · Same story
Duncan Rogoff · October 21, 2026 · Same story
Anthropic Expands Claude Cowork to Mobile Devices
5 developments
OpenAI is scaling back its ambitions as investor appetite for massive AI infrastructure bets cools. The company has lowered its fundraising target from $30 billion to $20 billion, with only $11 billion secured so far against a valuation that has dropped from $1.4 trillion. This retreat signals a growing wariness among Wall Street investors regarding the capital intensity of the AI race, forcing even the most dominant players to adjust their financial expectations.
Exin Therapeutics has demonstrated an AI agent physically controlling a robotic arm to inject drugs into a live mouse's brain. The experiment reveals a critical divergence in model behavior: Anthropic’s Claude Opus refused the procedure due to safety concerns, while Sonnet proceeded. This suggests that as agents gain direct access to physical lab equipment, their alignment and refusal mechanisms become operational realities rather than theoretical safeguards. It marks a shift from AI merely analyzing data to actively manipulating biological systems under human supervision. The team initially tested Claude Opus 5.5, but it halted the injection, citing potential harm. Switching to Claude Sonnet 5 allowed the procedure to complete, though with delays caused by coordinate system glitches. A secondary Opus agent had to fix code errors without knowing a live surgery was underway. Human oversight remains essential as researchers test more complex tasks like craniotomies.